Is Glaxo's niche-drug strategy a sleeper?

GlaxoSmithKline CEO Andrew Witty (photo) answers a U.K. broadcaster's question: If Glaxo isn't going to develop blockbuster meds, then who is? It doesn't impress PharmaGossip, which proposes the broadcast as a preternaturally effective insomnia treatment. (Video) Report | Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.